echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sinopharm Modern Nifedipine Controlled-Release Tablets and Omeprazole Enteric-Coated Tablets Pass the Consistency Evaluation of Generic Drugs

    Sinopharm Modern Nifedipine Controlled-Release Tablets and Omeprazole Enteric-Coated Tablets Pass the Consistency Evaluation of Generic Drugs

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 22, Sinopharm Modern issued an announcement stating that the company and its wholly-owned subsidiary Sinogong Co.
    , Ltd.
    respectively received the "Approval Notice for Supplementary Drug Application" approved and issued by the State Drug Administration, and approved nifedipine controlled-release tablets (30mg).
    ) and omeprazole enteric-coated tablets (20mg) were evaluated by the consistency of generic drug quality and efficacy
    .

    1.
    Nifedipine Controlled Release Tablets

    1.
    Nifedipine Controlled Release Tablets

    Nifedipine is mainly used for the treatment of hypertension and coronary heart disease (chronic stable angina)
    .


    Nifedipine controlled-release tablets use the membrane-regulated push-pull osmotic pump principle, and the drug is released at a zero-order rate, which can effectively improve the "peak and valley" phenomenon of blood drug concentration.


    According to the Minet database, the sales of nifedipine controlled-release tablets in 2020 in public hospitals nationwide will be approximately RMB 2.
    177 billion
    .


    The sales revenue of the company's nifedipine controlled-release tablets in 2020 is approximately RMB 1.


    According to the CDE website, the companies that have passed or are deemed to have passed the consistency evaluation of nifedipine controlled-release tablets include Beijing Honglin Pharmaceutical Co.
    , Ltd.
    and Guangzhou Yipinhong Pharmaceutical Co.
    ,
    Ltd.


    Up to now, the company has invested about RMB 28.


    2.
    Omeprazole enteric-coated tablets

    2.
    Omeprazole enteric-coated tablets

    Omeprazole is mainly used for the treatment of duodenal ulcer, Zollinger-Ellison syndrome (gastrinoma), gastric ulcer and reflux esophagitis, etc.
    It can also be combined with amoxicillin and clindamycin or with Metronidazole is used in combination with clarithromycin to kill Helicobacter pylori
    .

    According to the data from the PDB Drug Comprehensive Database, the sales of omeprazole enteric-coated tablets in domestic sample hospitals in the past three years were RMB 62.
    9499 million
    .


    In the past three years, the sales revenue of omeprazole enteric-coated tablets of Guogong Co.


    According to the CDE website, there are currently Hunan Fangsheng Pharmaceutical Co.
    , Ltd.
    and Shandong New Times Pharmaceutical Co.
    , Ltd.
    that have passed or are deemed to pass the consistency evaluation of omeprazole enteric-coated tablets
    .


    Up to now, Guogong Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.